Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients.
about
Reviewing 15 years of experience with sirolimusSystemic meta-analysis assessing the short term applicability of early conversion to mammalian target of rapamycin inhibitors in kidney transplant.Rapamycin promotes Schwann cell migration and nerve growth factor secretion.Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.Association of the PPP3CA c.249G>A variant with clinical outcomes of tacrolimus-based therapy in kidney transplant recipients.Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: a systematic review and meta-analysis.CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.Calcineurin Inhibitor Minimization, Conversion, Withdrawal, and Avoidance Strategies in Renal Transplantation: A Systematic Review and Meta-Analysis.Influence of ABCC2, CYP2C8, and CYP2J2 Polymorphisms on Tacrolimus and Mycophenolate Sodium-Based Treatment in Brazilian Kidney Transplant Recipients.mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term OutcomesOpen-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients.Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation.Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) - results of a randomized controlled clinical trial.Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial.Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA.Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months.
P2860
Q28080955-583EA54B-5E0E-48FF-9883-DDA958E4D54DQ33617408-900A67CC-DCE9-4A21-A885-8575A2574FC0Q34096079-A1DC2313-DAA3-486E-9342-3D16475CA640Q36051817-32C11AF4-AEDD-4C85-9D28-4761A33248F3Q37745691-62AA2246-1D12-43E1-9F3A-504116171506Q38241710-1B8007E3-A989-4DFA-AC2A-81B55EC7D123Q38242068-55DC21F9-3CB6-4E3B-A5FF-43E0836359F2Q38747503-B199B4C9-DDBB-4A92-8D47-9A002449F1FBQ38779769-AF3685D1-8DF7-4D92-9162-64F6BFEC2068Q38896041-07575FC2-88CC-44C0-87AA-D0468FC6ADA9Q38962103-B9FB21C8-DC66-49CC-8F9D-353B436DC118Q40073566-E7B68A44-AC18-4CA8-A168-AFB20404BAADQ41313340-F7956185-8F5C-418A-A9E2-30FFC05F1ED9Q42418219-F3F5D078-C8B7-49F8-96B2-E4DA25D5D69CQ42679895-2D08602F-5342-4221-9120-28D194D16406Q47309233-91B3CAE6-CD9D-4AA0-9049-0E69A1E4CB3FQ50997883-7C8841E7-0136-42AF-AE4C-FF7AE2AD4A77Q52874072-1F1CF685-4156-4CB8-896A-2009FBC37EA0Q53570157-950D98A7-EC77-4067-9B6F-510EFCA6BC9CQ55265769-85989026-4617-4241-888A-32425EA660DD
P2860
Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Planned randomized conversion ...... kidney transplant recipients.
@en
Planned randomized conversion ...... kidney transplant recipients.
@nl
type
label
Planned randomized conversion ...... kidney transplant recipients.
@en
Planned randomized conversion ...... kidney transplant recipients.
@nl
prefLabel
Planned randomized conversion ...... kidney transplant recipients.
@en
Planned randomized conversion ...... kidney transplant recipients.
@nl
P2093
P2860
P356
P1476
Planned randomized conversion ...... kidney transplant recipients.
@en
P2093
C R Felipe
D D B M de Carvalho
F L C Contieri
J O M Pestana
V D Garcia
P2860
P304
P356
10.1111/AJT.12481
P407
P577
2013-10-30T00:00:00Z